Apomorphine Hcl Tablet Suppliers & Bulk Manufacturers

Available Forms: Sublingual Tablets

Available Strengths: 10 mg, 15 mg, 20 mg, 25 mg,30 mg

Reference Brands: Kynmobi (USA/EU)

Category: Neurology

Apomorphine is a dopamine agonist used to treat “off” episodes in Parkinson’s disease. It works by stimulating dopamine receptors in the brain to improve motor function when oral medications are less effective. Available as subcutaneous injections (Apokyn, APO-go, Onapgo) and sublingual films (Kynmobi), it provides rapid relief from motor fluctuations. Apomorphine is not a narcotic and is specifically targeted for neurological therapy. Apomorphine HCl Tablet is available in Sublingual Tablets and strengths such as 10 mg, 15 mg, 20 mg, 25 mg,30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Apomorphine HCl Tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Apomorphine HCl Tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Apomorphine is a potent non-selective dopamine agonist used primarily in the management of Parkinson’s disease. It activates D2-like dopamine receptors and, to a lesser extent, D1-like receptors, helping to improve motor function during “OFF” episodes when standard oral dopaminergic therapy is temporarily ineffective. In addition to its dopaminergic activity, apomorphine also exhibits high-affinity antagonism at 5-HT2 and α-adrenergic receptors, contributing to its complex pharmacological profile.

Chemically, apomorphine is an aporphine alkaloid originally derived from Nymphaea caerulea (blue lotus) and historically produced as a morphine decomposition product, though it does not contain morphine nor interact with opioid receptors. The name reflects its origin as a morphine derivative, with the “apo-” prefix indicating its chemical modification. Apomorphine’s diverse receptor interactions make it a valuable therapeutic agent for rapid symptom control in Parkinson’s disease, particularly for acute motor fluctuations, offering a targeted and effective approach to improving patient quality of life.